. 16 Sparreboom A van Tellingen O Nooijen WJ . Preclinical pharmacokinetics of paclita el and docetaxel . Anticancer Drugs 1998 ; 9 : 1 – 17 . 17 Bruno R Hille D Riva A . Population pharmacokinetics/pharmacodynamics of docetaxel in
Search Results
Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian, Jun Lu, Xue-Yan Zhang, Hui-Min Wang, Bo Yan, Bo Zhang, Shu-Yuan Wang, Fang Hu, Chang-Hui Li, Hua Zhong, and Bao-Hui Han
POPLAR trials has been described previously. 8 , 10 , 11 Patients who had previously received chemotherapy for stage IIIB or IV NSCLC were randomized (1:1) to treatment with atezolizumab (1,200 mg fixed dose) or docetaxel (75 mg/m 2 ). Because the aim of
Baijun Dong, Liancheng Fan, Bin Yang, Wei Chen, Yonghong Li, Kaijie Wu, Fengbo Zhang, Haiying Dong, Huihua Cheng, Jiahua Pan, Yinjie Zhu, Chenfei Chi, Liang Dong, Jianjun Sha, Lei Li, Xudong Yao, and Wei Xue
.5%), respectively. Patients were also categorized according to treatment after blood collection. Baseline sample numbers from those receiving treatment (after baseline ctDNA collection) were as follows: abiraterone (n=58), docetaxel (n=66), platinum
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera
treatment for patients with AGC. 5 In the V325 randomized clinical trial (RCT), the DCF (docetaxel, cisplatin, fluorouracil) regimen was superior to CF (cisplatin, fluorouracil) in patients with a good performance status (PS) and preserved organ function
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
is well described. 8 – 11 However, the potential for overtreatment and toxicity associated with use of third-generation chemotherapy regimens is of concern. After the E1199 clinical trial 12 established the equivalence of docetaxel every 3 weeks and
Vivek Subbiah, Ulka Vaishampayan, Sonam Puri, Lanjia Lin, Mark Chao, Giri Ramsingh, Shivaani Kummar, James F Strauss, and Sandip P Patel
signals on tumor cells, leading to synergistic antitumor activity when combined with magrolimab. This study ( NCT04827576 ) evaluates the safety, tolerability, and efficacy of magrolimab with docetaxel in relapsed/refractory metastatic urothelial cancer
Dawn Goetz
/mL but then sharply increased to 35 ng/mL in February 2010. Imaging showed increased bony metastases and new lymph node involvement. The patient was then started on docetaxel, 75 mg/m 2 , with prednisone every 3 weeks and continued therapy with
Nicolas Batty, Naveen Yarlagadda, and Roberto Pili
docetaxel at 75 mg/m 2 and prednisone and completed 13 cycles with clinical benefit. This treatment was followed by a short drug holiday. Unfortunately, restaging CT revealed new liver lesions. A second line of chemotherapy with cabazitaxel was then
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
Evaluation of docetaxel dose reductions have also yielded conflicting results. 20 , 21 Currently, a paucity of data exists for dose adjustments affecting survival for third-generation anthracycline/taxane-based regimens. Furthermore, for sequential regimens
Komal Jhaveri and Francisco J. Esteva
and docetaxel in a phase Ib trial. 25 One patient with prostate cancer experienced a partial response and more than 50% of patients experienced SD after 4 cycles of treatment with combination therapy. DLTs of grade 3 diarrhea and grade 4 febrile
